| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/19/2005 | CN1568189A [[2-(amino-3, 4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 01/19/2005 | CN1568184A Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome |
| 01/19/2005 | CN1568183A Citalopram for the treatment of elevated blood pressure |
| 01/19/2005 | CN1568177A Anti-microbial composition comprising a metal ion chelating agent |
| 01/19/2005 | CN1566134A Non-structural protein gene of coronavirus and use thereof |
| 01/19/2005 | CN1565627A Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation |
| 01/19/2005 | CN1565619A Novel usage of soluble P-lectin and anthrax lethal toxin |
| 01/19/2005 | CN1565474A Biochemical nucleic acid fulvic acid oral liquid production method |
| 01/19/2005 | CN1184968C Antibiotic compositions for treatment of the eye, ear and nose |
| 01/19/2005 | CN1184961C Use of EGF-R antagonists in preparing drug |
| 01/19/2005 | CN1184903C Method for stabilizing liquid nutritional products and products so stabilized |
| 01/18/2005 | US6844349 Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 01/18/2005 | US6844313 With protein or phosphoglyceride as aqueous solution; in vitro fertilization |
| 01/18/2005 | US6844189 Chromosome 17P-linked prostate cancer susceptibility gene |
| 01/18/2005 | US6844180 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 01/18/2005 | US6844175 Methods of inhibition using glycosyl sulfotransferase-3 |
| 01/18/2005 | US6844153 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/18/2005 | US6843991 Use of the M3 protein of MHV68 to block binding of a chemokine to its receptor |
| 01/18/2005 | US6843989 Administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand |
| 01/18/2005 | US6843961 Deactivation pathogens; using riboflavin sensitizers; exposure to light source |
| 01/18/2005 | US6843372 Antihistamine/decongestant regimens for treating rhinitis |
| 01/18/2005 | CA2367127C Macrocyclic peptides active against the hepatitis c virus |
| 01/13/2005 | WO2005003295A2 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | WO2005002672A2 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | WO2005002599A1 Buffered compositions for dialysis |
| 01/13/2005 | WO2005002598A1 Mouth and/or throat wash |
| 01/13/2005 | WO2005002597A1 Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| 01/13/2005 | WO2005002578A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 01/13/2005 | WO2005002571A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | WO2005002555A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 01/13/2005 | WO2005002549A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 01/13/2005 | WO2005002543A1 Composition and method for the treatment of water related ear disorders |
| 01/13/2005 | WO2005002506A2 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites |
| 01/13/2005 | WO2004089379A3 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug |
| 01/13/2005 | WO2004082706A3 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 01/13/2005 | WO2004075907A3 Salutary compositions consisting of fungi containing lipids and thiocyanates |
| 01/13/2005 | WO2004073654A3 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 01/13/2005 | WO2004024097A8 Compositions and methods for the treatment of immune related diseases |
| 01/13/2005 | US20050010284 Method for decreasing bioprosthetic implant failure |
| 01/13/2005 | US20050009931 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 01/13/2005 | US20050009927 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| 01/13/2005 | US20050009925 Administering atomoxetine or its hydrochloride or a 3-(o-alkylthiophenoxy)-3-phenyl-N-alkylpropylamine for the treatment of cognitive failure, including that due to dementia, delirium and schizophrenia |
| 01/13/2005 | US20050009921 Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same |
| 01/13/2005 | US20050009916 E.g., dextromethorphan hydrobromide, amantadine, memantine, remacemide or riluzole; treating pain resulting from injury, trauma, lesion or other disorders in the spinal cord or brain |
| 01/13/2005 | US20050009896 Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 01/13/2005 | US20050009893 Administering a renin-angiotensin system inhibitor, particularly an angiotensin-receptor-blocker, an ACE-inhibitor, or a vasopeptidase inhibitor, especially incombination with a hypotensive agent |
| 01/13/2005 | US20050009891 Synergistic combination of a thiazolecarboxamide derivative, especially N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and an antiproliferative cytotoxic agent such as paclitaxel, procarbazine, mitoxantrone or an epidophyllotoxin |
| 01/13/2005 | US20050009868 Mixture of one or more RAR pan-antagonist compounds each of which has a high binding affinity to RAR alpha , RAR beta and RAR gamma; is administered to a population of cells to inhibit RAR mediated signalling and/or enhance RAR mediated repression leading to increased chondrogenesis. |
| 01/13/2005 | US20050009861 Inverse agonist has a functional efficacy at the alpha 1 and/or alpha 5 receptor subtypes of less than -5%, and the efficacy measured at the alpha 2 and alpha 3 receptor subtypes is greater than 5%, and is preferably a 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative |
| 01/13/2005 | US20050009856 Administering a compound which inhibits selectively mu opioid receptor activity or activation to treat conditions including Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease, and dyskinesias arising as a side-effect of a therapeutic agent. |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009848 Use of antivirals against inflammatory bowel diseases |
| 01/13/2005 | US20050009845 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 01/13/2005 | US20050009843 Thiazole derivatives of pyrido-1,2-a-pyrimidines, quinolones, pyridopyridazinoness, cinnolinones and naphthyridones; identifying a drug efflux pump expressed in a microorganism |
| 01/13/2005 | US20050009835 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors |
| 01/13/2005 | US20050009831 Chemical compounds |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009814 Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
| 01/13/2005 | US20050009810 synergistic combination of quinolinic antimalarial such as Chloroquine, Hydroxycloroquine, Mefloquine, or Quinine and HIV protease inhibitor such as indinavir, ritonavir, saquinavir, nelfinavir, lopinavir, amprenavir, fosamprenavir, tipranavir, atazanavir, or TMC-114 |
| 01/13/2005 | US20050009796 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 01/13/2005 | US20050009793 Treatment of liver disease with active vitamin D compounds |
| 01/13/2005 | US20050009791 Especially lysine, arginine, histidine, omithine and diaminobutyric acid; improved solubility for parenteral administration |
| 01/13/2005 | US20050009790 Ear and wound treatment |
| 01/13/2005 | US20050009779 Preparation for improving the action of receptors |
| 01/13/2005 | US20050009778 Method for treating retinal degeneration with purinergic receptor agonists |
| 01/13/2005 | US20050009754 Genetically engineered growth hormone; administering with antidepressant |
| 01/13/2005 | US20050009747 High purity lipopeptides |
| 01/13/2005 | US20050009744 Treatment of congestive heart failure |
| 01/13/2005 | US20050009736 Administering by hemodilution an aqueous cell-free polyalkylene oxide surface modified hemoglobin without intramolecular crosslinking; oxygen affinity greater than whole blood; blood disorders |
| 01/13/2005 | US20050009733 Synergistic mixture; stroke therapy |
| 01/13/2005 | US20050009730 Sleep disorders; side effect reduction |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009141 Epidermal differentiation factor |
| 01/13/2005 | US20050009062 Phosphodiesterase 10 |
| 01/13/2005 | US20050009056 Anti-infective therapy |
| 01/13/2005 | US20050009024 Using allelic variance in carboxypeptidase gene as diagnostic indicator of cardiovascular disease |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008717 Anti-neoplastic compositions comprising extracts of black cohosh |
| 01/13/2005 | US20050008707 Nanoparticulate megestrol formulations |
| 01/13/2005 | US20050008690 Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008685 Mixture containing liposome electrolytes |
| 01/13/2005 | US20050008679 synergistic efficacy; polar lipid supplement which contains antioxidants; soluble beta-glucan fiber; nutricine which enhances growth and/or strengthens the immune system; and a protein concentrate supplement such as whey protein concentrate |
| 01/13/2005 | US20050008678 Solid foods; creatine suspended in support matrix |
| 01/13/2005 | US20050008665 Mixture of antioxidant and hexadecenedicarboxylic acid |
| 01/13/2005 | US20050008644 Potentiation of the immune response |
| 01/13/2005 | US20050008643 Diagnostic methods and agents |
| 01/13/2005 | US20050008637 Cancer therapy; antiinflammatory agents; autoimmune disease |
| 01/13/2005 | US20050008636 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 01/13/2005 | US20050008633 Chemical and physical modulators of bioavailability of inhaled compositions |
| 01/13/2005 | CA2563362A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | CA2531142A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | CA2531136A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 01/13/2005 | CA2531083A1 Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma |
| 01/13/2005 | CA2530483A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 01/13/2005 | CA2530119A1 Buffered compositions for dialysis |
| 01/13/2005 | CA2529558A1 Agent inducing increase in bone mass |
| 01/13/2005 | CA2529510A1 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | CA2528084A1 Sppls as modifiers of the p53 pathway and methods of use |
| 01/13/2005 | CA2527908A1 Mylks as modifiers of branching morphogenesis and methods of use |